Oral Therapies for Treatment of Relapsing–remitting Multiple Sclerosis in Austria: A 2-Year Comparison Using an Inverse Probability Weighting Method

Journal of Neurology - Germany
doi 10.1007/s00415-020-09811-6
Full Text
Abstract

Available in full text

Categories
Neurology
Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Disease-Modifying Therapies in Relapsing–remitting Multiple Sclerosis

Neuropsychiatric Disease and Treatment
PsychiatryMental HealthBiological Psychiatry
2010English

Natalizumab: A New Treatment for Relapsing Remitting Multiple Sclerosis

Therapeutics and Clinical Risk Management
Chemical HealthPharmacologySafetyMedicineToxicologySafety ResearchPharmaceutics
2007English

No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing–Remitting Multiple Sclerosis

Advances in Therapy
MedicinePharmacology
2014English

Intestinal Permeability in Relapsing-Remitting Multiple Sclerosis

Neurotherapeutics
NeurologyPharmacology
2017English

Emerging Therapies for Relapsing Multiple Sclerosis

Archives of Neurology
2009English

A Type 2 Biomarker Separates Relapsing-Remitting From Secondary Progressive Multiple Sclerosis

Neurology
Neurology
2014English

Intravenous Immunoglobulin G for the Treatment of Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis

European Journal of Neurology
Neurology
2002English

PND14 Budgetary Impact of the Treatment of Relapsing-Remitting Multiple Sclerosis in Spain

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis

Archives of Neurology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy